抗血管生成剂在结肠直肠癌中的当前作用
Debora Basile1, Paola Di Nardo2, Maria Grazia Daffinà3
1Unit of Medical Oncology, San Giovanni Di Dio Hospital-Crotone, 88900 Crotone, Italy.
International journal of molecular sciences
|December 11, 2025
概括
转移性结直肠癌 (mCRC) 治疗正在使用新型抗血管原体药物,如fruquintinib. 将这些与免疫疗法相结合,有望改善晚期结直肠癌患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 大肠直肠癌 (CRC) 是全球领先的癌症,在诊断时显著比例呈现为转移性 (mCRC) 或发展复发.
- 标准的mCRC治疗包括化疗加上分子向药物,而抗血管性药物起着关键作用.
- 瘤血管生成,缺氧和免疫反应相互关联,影响癌症的进展.
研究的目的:
- 审查目前转移性结直肠癌的治疗环境.
- 突出新兴的治疗策略,包括新的抗血管原体和组合.
- 讨论创新治疗的潜力,以改善mCRC患者的治疗结果.
主要方法:
- 这是一个叙述性综述,综合了关于mCRC治疗的现有证据.
- 专注于抗血管原剂,免疫疗法和新分子的作用.
- 讨论了新兴疗法 (如fruquintinib) 的临床疗效数据.
主要成果:
- 抗血管原剂是mCRC管理的组成部分.
- 抗血管原剂与免疫检查点抑制剂的组合显示出有前途.
- 新型抗血管原剂弗鲁昆丁尼布在mCRC中已经证明了临床疗效.
结论:
- 对于mCRC的治疗场景正在经历显著的演变.
- 创新的组合和药物,如fruquintinib,为患者提供了新的希望.
- 需要进一步的研究来解决剩余的挑战,并优化治疗策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mechanism of Angiogenesis
6.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.6K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


